1. Home
  2. SII vs SUPN Comparison

SII vs SUPN Comparison

Compare SII & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sprott Inc.

SII

Sprott Inc.

N/A

Current Price

$126.34

Market Cap

2.7B

Sector

Finance

ML Signal

N/A

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

N/A

Current Price

$41.69

Market Cap

2.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SII
SUPN
Founded
2008
2005
Country
Canada
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.8B
IPO Year
2011
2010

Fundamental Metrics

Financial Performance
Metric
SII
SUPN
Price
$126.34
$41.69
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$132.00
$61.60
AVG Volume (30 Days)
152.9K
511.5K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
1.11%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$392,755,000.00
Revenue This Year
$26.03
$22.70
Revenue Next Year
$11.83
$19.14
P/E Ratio
$63.42
N/A
Revenue Growth
N/A
N/A
52 Week Low
$69.08
$41.50
52 Week High
$169.63
$59.68

Technical Indicators

Market Signals
Indicator
SII
SUPN
Relative Strength Index (RSI) 52.94 29.75
Support Level $124.54 N/A
Resistance Level $137.62 $52.33
Average True Range (ATR) 4.30 1.28
MACD -0.96 -0.38
Stochastic Oscillator 23.40 2.24

Price Performance

Historical Comparison
SII
SUPN

About SII Sprott Inc.

Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Share on Social Networks: